Udicil
Udicil Brand names, Udicil Analogs
- AR3
- Alexan
- Ara-C
- AraC
- Arabinocytidine
- Arabinofuranosylcytosine
- Arabinosylcytosine
- Arabitin
- Aracytidine
- Aracytin
- Aracytine
- Arafcyt
- Beta-cytosine arabinoside
- Citarabina [INN-Spanish]
- Cytarabin
- Cytarabina
- Cytarabine (JP14/USP)
- Cytarabine [USAN:BAN:INN:JAN]
- Cytarabine(USAN)
- Cytarabinoside
- Cytarabinum [INN-Latin]
- Cytarbel
- Cytosar
- Cytosar-U
- Cytosine 1-beta-D-arabinofuranoside
- Cytosine arabinofuranoside
- Cytosine arabinose
- Cytosine arabinoside
- Cytosine arabinoside (VAN)
- Cytosine beta-D-arabinoside
- Cytosine, 1-beta-D-arabinosyl-
- Cytosine, beta-D-arabinoside
- Cytosine-1-beta-D-arabinofuranoside
- Cytosine-beta-D-arabinofuranoside
- Cytosine-beta-arabinoside
- Depocyt
- Depocyt (TN)
- Depocyt (liposomal)
- Erpalfa
- Iretin
- Spongocytidine
- Tarabine
- Udicil
- beta-Arabinosylcytosine
- beta-D-Arabinosylcytosine
Udicil Brand Names Mixture
- No information avaliable
Udicil Chemical_Formula
C9H13N3O5
Udicil RX_link
http://www.rxlist.com/cgi/generic3/cytarabine.htm
Udicil fda sheet
Udicil msds (material safety sheet)
Udicil Synthesis Reference
Krenitski, et al; Carbohydr.Res.; 97, 139-146(1981)
Udicil Molecular Weight
243.217 g/mol
Udicil Melting Point
212-213oC
Udicil H2O Solubility
Freely soluble
Udicil State
Solid
Udicil LogP
-2.712
Udicil Dosage Forms
Injectable solution
Udicil Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Udicil Pharmacology
Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.
Udicil Absorption
Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.
Udicil side effects and Toxicity
Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.
Udicil Patient Information
This medicine is a type of chemotherapy for treating cancers of the
blood and certain other cancers. This medicine interfers with the
way cancer cells grow, Take your doses on a regular scheduled time
and DO NOT take this medicine more often than directed by your health
care provider. Finish the full course prescribed by your health care
provider. DO NOT stop taking this medicine unless diredted to do so
by your health care provider. While taking this medicine, you make
get infection more easily. Call your doctor if you get a fever, chills,
or sore throat. Drink plenty of water with this medicine.
blood and certain other cancers. This medicine interfers with the
way cancer cells grow, Take your doses on a regular scheduled time
and DO NOT take this medicine more often than directed by your health
care provider. Finish the full course prescribed by your health care
provider. DO NOT stop taking this medicine unless diredted to do so
by your health care provider. While taking this medicine, you make
get infection more easily. Call your doctor if you get a fever, chills,
or sore throat. Drink plenty of water with this medicine.
Udicil Organisms Affected
Humans and other mammals
